Bisphosphonate-induced maxillofacial osteonecrosis in osteoporotic individuals. A possibilidade de osteonecrose dos maxilares em pacientes expostos a bisfosfonatos nitrogenados foi descrita pela primeira vez em Descritores: Osteoporose; Bisfosfonatos; Ossos da Face. Bisphosphonate-related osteonecrosis of the maxillae may be an important complication of long-term osteoporosis treatment. The possibility of osteonecrosis of the maxillae in patients exposed to nitrogenated bisphosphonates was first described in
|Published (Last):||8 September 2011|
|PDF File Size:||12.19 Mb|
|ePub File Size:||7.65 Mb|
|Price:||Free* [*Free Regsitration Required]|
Bisphosphonate-induced maxillofacial osteonecrosis in osteoporotic individuals. A possibilidade de osteonecrose dos maxilares em pacientes expostos a bisfosfonatos nitrogenados foi descrita pela primeira vez em Descritores: Osteoporose; Bisfosfonatos; Ossos da Face.
Bisphosphonate-related osteonecrosis of the maxillae may be an important complication of long-term osteoporosis treatment. The possibility of osteonecrosis of the maxillae in patients exposed to nitrogenated bisphosphonates was first described in Since then, case reports and retrospective studies have demonstrated higher percentages of occurrence of osteonecrosis in patients who have used or are using bisphosphonates.
Although this complication may be spontaneous, invasive oral procedures have a role as risk factors associated with dental procedures such as tooth extractions and other bone operations. In addition, tooth infections and periodontal disease have been reported to be the main risk factors for development of bisphosphonate-induced osteonecrosis of the maxillae.
For this reason, dentists, general clinicians, orthopedists, geriatricians and oral-maxillofacial surgeons need to be aware of this problem and work in a multidisciplinary environment, thereby stimulating early diagnosis and prevention of further potential cases. Keywords: Osteoporosis; Bisphosphonates; Facial Bones.
South Med J. Vestergaard P, Thomsen SV. Treating postmenopausal osteoporosis in women at increased risk of fracture - critical appraisal of bazedoxifene: a review. Int J Women Health. Osteoporosis: impact on health and economics. Nat Rev Rheumatol. Osteoporosis in men. Am Fam Physician. Physiological bases of bone regeneration I. Histology and physiology of bone tissue. The effects of bisphosphonates on osteoblasts in vitro.
Epstein S. Update of current therapeutic options for the treatment of postmenopausal osteoporosis. Clin Ther. Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Ther Clin Risk Manag. Oppermann U. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Bisphosphonate mechanism of action. Curr Rheumatol Rep. Migliorati CA. Bisphosphanates and oral cavity avascular bone necrosis.
J Clin Oncol. Marx RE. Pamidronate Aredia and zoledronate Zometa induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. Osteonecrosis of the jaws associated with cancer chemotherapy. Bisphosphonates and avascular necrosis of the jaws. Aust Dent J. Melo MD, Obeid G. Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: strategies for prevention and early recognition.
J Am Dent Assoc. Osteonecrosis of the maxilla in a patient with a history of bisphosphonate therapy. J Can Dent Assoc. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Bisphosphonate-associated oral osteonecrosis. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw - update.
Aust Endod J. Effectiveness of pretreatment in decreasing adverse events associated with pamidronate in children and adolescents. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates?
J Craniomaxillofac Surg. Bisphosphonate osteochemonecrosis bis-phossy jaw : is this phossy jaw of the 21st century? Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: a new clinical entity.
Am J Med. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws.
Ann Intern Med. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Bisphosphonate-related osteonecrosis of the jaw associated with dental implants.
Madrid C, Sanz M. What impact do systemically administrated bisphosphonates have on oral implant therapy? A systematic review. Clin Oral Implants Res. Javed F, Almas K. Osseointegration of dental implants in patients undergoing bisphosphonate treatment: a literature review. J Periodontol. All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License. Services on Demand Journal. How to cite this article.
ARCHIVES OF HEALTH INVESTIGATION
Osteonecrosis de los maxilares asociada al empleo de bifosfonatos. Galdeano Arenas 1 , J. Jefe de Servicio. The main pharmacological effect of bisphosphonates is the inhibition of bone resorption, mediated by a decreased function of osteoclasts without interfering in bone formation and mineralization. These drugs are used worldwide, with clear and clinically proven benefits. Several publications within the last three years consider osteonecrosis of the jaw to be associated with bisphosphonate therapy as a result of their extensive use.